Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
Enliven Therapeutics (Nasdaq: ELVN) announced upcoming presentations of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The trial focuses on ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated Chronic Myeloid Leukemia.
The data will be presented in both oral and poster formats by Dr. Michael J. Mauro on September 3-4, 2025, at the George R. Brown Convention Center in Houston. This presentation is an encore of previously presented data at the European Hematology Association (EHA) 2025 Congress.
Enliven Therapeutics (Nasdaq: ELVN) ha annunciato la presentazione di dati dello studio clinico ENABLE Fase 1a/1b su ELVN-001 al Congresso Annuale SOHO 2025 (Society of Hematologic Oncology). Lo studio riguarda ELVN-001, un inibitore selettivo del sito attivo di BCR::ABL1, in pazienti con Leucemia Mieloide Cronica precedentemente trattata.
I risultati saranno esposti in formato orale e poster dal Dr. Michael J. Mauro il 3-4 settembre 2025 presso il George R. Brown Convention Center di Houston. Si tratta di una replica dei dati gi脿 presentati al Congresso dell'Associazione Europea di Ematologia (EHA) 2025.
Enliven Therapeutics (Nasdaq: ELVN) anunci贸 la presentaci贸n de datos de su ensayo cl铆nico ENABLE Fase 1a/1b sobre ELVN-001 en la Reuni贸n Anual SOHO 2025 (Society of Hematologic Oncology). El ensayo eval煤a ELVN-001, un inhibidor selectivo del sitio activo de BCR::ABL1, en pacientes con Leucemia Mieloide Cr贸nica previamente tratada.
Los datos ser谩n presentados en formatos oral y p贸ster por el Dr. Michael J. Mauro el 3 y 4 de septiembre de 2025 en el George R. Brown Convention Center de Houston. Es una repetici贸n de los datos ya mostrados en el Congreso de la Asociaci贸n Europea de Hematolog铆a (EHA) 2025.
Enliven Therapeutics (雮橃姢雼�: ELVN)鞚� ELVN-001鞐� 雽�頃� ENABLE 1a/1b靸� 鞛勳儊鞁滍棙 雿办澊韯半ゼ SOHO 2025 鞐半須岇潣(Society of Hematologic Oncology)鞐愳劀 氚滍憸頃� 鞓堨爼鞚措澕瓿� 氚滍憸頄堨姷雼堧嫟. 頃措嫻 鞛勳儊鞚� BCR::ABL1鞚� 頇滌劚 攵�鞙勳棎 靹犿儩鞝侅溂搿� 鞛戩毄頃橂姅 鞏奠牅鞝� ELVN-001鞚� 鞚挫爠鞐� 旃橂毳� 氚涭潃 毵岇劚 瓿垬靹� 氚表槇氤� 頇橃瀽毳� 雽�靸侅溂搿� 頃╇媹雼�.
鞚� 雿办澊韯半姅 Dr. Michael J. Mauro臧� 2025雲� 9鞗� 3~4鞚� 頊挫姢韯挫潣 George R. Brown Convention Center鞐愳劀 甑憪 氚� 韽姢韯� 順曥嫕鞙茧 氚滍憸頃╇媹雼�. 鞚措姅 鞙犽熃順堨暋頃欗殞(EHA) 2025鞐愳劀 氚滍憸頄堧崢 雮挫毄鞚� 雼れ嫓 靹犽炒鞚措姅 瓴冹瀰雼堧嫟.
Enliven Therapeutics (Nasdaq听: ELVN) a annonc茅 la pr茅sentation de donn茅es issues de son essai clinique ENABLE Phase 1a/1b sur ELVN-001 lors de la r茅union annuelle SOHO 2025 (Society of Hematologic Oncology). L'essai porte sur ELVN-001, un inhibiteur s茅lectif du site actif de BCR::ABL1, chez des patients atteints de leuc茅mie my茅lo茂de chronique ayant d茅j脿 re莽u un traitement.
Les donn茅es seront pr茅sent茅es sous formats oral et poster par le Dr Michael J. Mauro les 3 et 4 septembre 2025 au George R. Brown Convention Center de Houston. Il s'agit d'une rediffusion des r茅sultats d茅j脿 pr茅sent茅s au Congr猫s de l'Association Europ茅enne d'H茅matologie (EHA) 2025.
Enliven Therapeutics (Nasdaq: ELVN) k眉ndigte die Pr盲sentation von Daten aus der ENABLE Phase 1a/1b-Studie zu ELVN-001 auf dem SOHO 2025 Annual Meeting (Society of Hematologic Oncology) an. Die Studie untersucht ELVN-001, einen selektiven aktiven Standortinhibitor von BCR::ABL1, bei zuvor behandelten Patienten mit chronischer myeloischer Leuk盲mie.
Die Daten werden am 3. und 4. September 2025 von Dr. Michael J. Mauro in Vortr盲gen und Poster-Sessions im George R. Brown Convention Center in Houston vorgestellt. Es handelt sich um eine Wiederholung der bereits auf dem EHA 2025 vorgestellten Daten.
- None.
- None.
Details of the presentation are as follows:
Title:听ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia
Presenter: Michael J. Mauro, M.D.
Poster Session Date/Time: Wednesday, September 3, 6:25 p.m. CDT
Poster Location: Hall B3, Level 3
Poster Number: CML-575
Oral Session Title: Session V: Chronic Myeloid Leukemia
Oral Session Date/Time: Thursday, September 4, 11:40 鈥� 11:50 a.m. CDT
Following the presentation, a copy will be available on the "" section of the Company's website at .
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and potential of our small molecule therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation: Enliven's limited operating history and resources; uncertainty in our ability to advance product candidates through clinical development, obtain regulatory approvals, and successfully commercialize or license them; uncertainty of preclinical and early clinical results, which may not predict success of later clinical trials; potential delays or challenges in clinical trial enrollment, data reliability, and patient retention; potential competition from other therapies; the decision to seek collaborations and develop combination therapies; the ability to hire and retain key personnel; our ability to obtain, maintain and enforce intellectual property for our product candidates; our reliance on third parties for manufacturing, research, and partnerships; geopolitical, market, and macroeconomic conditions; the ability to secure additional capital to support Enliven's operations and R&D; and other risks and uncertainties, including those more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), which may be found in the section titled "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and 10-Q filed with the SEC and in Enliven's future reports to be filed with the SEC. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
View original content to download multimedia:
SOURCE Enliven Therapeutics, Inc.
FAQ
When will Enliven Therapeutics (ELVN) present at SOHO 2025?
What is ELVN-001 being studied for in the ENABLE trial?
Who will present Enliven's ELVN-001 data at SOHO 2025?
Where can investors find Enliven's SOHO 2025 presentation materials?
